Helix BioPharma Corp. (HBPCF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Helix BioPharma Corp. (HBPCF) with AI Score 45/100 (Weak). Helix BioPharma Corp. is a Canadian immune-oncology company focused on developing L-DOS47 for non-small cell lung cancer and V-DOS47 targeting vascular epithelial growth factor receptor 2. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Helix BioPharma Corp. (HBPCF) Healthcare & Pipeline Overview
Helix BioPharma Corp., an immune-oncology company based in Canada, is focused on the development of targeted therapies for cancer, primarily L-DOS47 for non-small cell lung cancer and V-DOS47. With collaborations aimed at enhancing treatment efficacy, the company operates in a competitive biotechnology landscape with a small team of 7 employees.
Investment Thesis
Helix BioPharma Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on immune-oncology, particularly the development of L-DOS47 and V-DOS47, addresses a significant unmet need in cancer treatment. Key value drivers include successful clinical trial outcomes and potential partnerships with larger pharmaceutical companies. The collaborations with Moffitt Cancer Center and University Hospital Tuebingen could accelerate drug development and validation. However, the company's small size and limited financial resources pose significant risks. The negative P/E ratio of -30.96 reflects the company's current lack of profitability. Successful navigation of clinical trials and securing additional funding are critical for the company's long-term success. Investors should closely monitor clinical trial results and partnership developments.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.13 billion, indicating a small-cap company with potential for growth.
- Negative P/E ratio of -30.96, reflecting the company's current lack of profitability and ongoing investment in research and development.
- Beta of -0.39, suggesting the stock is less volatile than the market, which may appeal to risk-averse investors.
- Focus on immune-oncology, a rapidly growing field with significant potential for innovative cancer therapies.
- Collaboration agreements with Moffitt Cancer Center and University Hospital Tuebingen, providing access to expertise and resources for drug development.
Competitors & Peers
Strengths
- Innovative DOS47 platform targeting cancer cells.
- Collaboration agreements with reputable cancer research institutions.
- Focus on the rapidly growing field of immune-oncology.
- Patent protection for key drug candidates.
Weaknesses
- Small size and limited financial resources.
- Dependence on successful clinical trial outcomes.
- Negative P/E ratio indicating lack of profitability.
- OTC market listing, which may limit investor access.
Catalysts
- Upcoming: Clinical trial results for L-DOS47 in non-small cell lung cancer, expected in late 2026.
- Ongoing: Collaboration with Moffitt Cancer Center to investigate L-DOS47 in combination with immune checkpoint inhibitors.
- Ongoing: Collaboration with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models.
- Upcoming: Potential strategic partnerships with larger pharmaceutical companies, anticipated in 2027.
- Upcoming: Regulatory submissions for L-DOS47, expected in 2028 if clinical trials are successful.
Risks
- Potential: Clinical trial failures for L-DOS47 or V-DOS47.
- Ongoing: Competition from larger, more established pharmaceutical companies.
- Ongoing: Regulatory hurdles and lengthy approval processes.
- Potential: Patent expirations and generic competition.
- Ongoing: Limited financial resources and dependence on additional funding.
Growth Opportunities
- Expansion of L-DOS47 clinical trials: The primary growth opportunity lies in the successful completion and expansion of clinical trials for L-DOS47 in the treatment of non-small cell lung cancer. Positive trial results could lead to regulatory approval and commercialization, potentially capturing a significant share of the NSCLC treatment market, which is projected to reach billions of dollars globally. The timeline for this growth opportunity depends on the pace of clinical trial progress and regulatory review.
- Development of V-DOS47: The development of V-DOS47, targeting VEGFR2, represents another growth avenue. Successful preclinical and clinical development could lead to a new treatment option for cancers driven by angiogenesis. The market for anti-angiogenic therapies is substantial, offering significant revenue potential. The timeline for this growth opportunity is contingent on research and development progress and regulatory approvals.
- Strategic partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide Helix BioPharma with access to additional funding, expertise, and distribution channels. These partnerships could accelerate the development and commercialization of its drug candidates. The potential market size would depend on the specific terms of the partnership and the target market for the partnered drug. The timeline for securing partnerships is uncertain but could occur in the near to medium term.
- Expansion into new cancer indications: Expanding the application of the DOS47 platform to other cancer indications represents a long-term growth opportunity. This would require further research and development, but could significantly broaden the company's market reach. The market size for new cancer indications would vary depending on the specific cancer type. The timeline for this growth opportunity is likely several years.
- Combination therapies: Investigating and developing combination therapies involving L-DOS47 and other cancer treatments, such as immune checkpoint inhibitors, could enhance treatment efficacy and expand the market opportunity. The collaboration with Moffitt Cancer Center is focused on exploring this potential. The market size for combination therapies is substantial, as they often provide improved outcomes compared to single-agent treatments. The timeline for this growth opportunity depends on the results of ongoing research and clinical trials.
Opportunities
- Expansion of clinical trials for L-DOS47 and V-DOS47.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new cancer indications.
- Development of combination therapies with immune checkpoint inhibitors.
Threats
- Competition from larger, more established pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Clinical trial failures.
- Patent expirations and generic competition.
Competitive Advantages
- Proprietary DOS47 platform: The DOS47 platform represents a unique approach to cancer therapy, providing a potential competitive advantage.
- Patent protection: Patents on L-DOS47 and V-DOS47 provide exclusivity and protect the company's intellectual property.
- Collaboration agreements: Collaborations with leading cancer research institutions enhance the company's credibility and provide access to valuable expertise and resources.
- Focus on immune-oncology: The focus on immune-oncology positions the company in a rapidly growing and innovative field.
About HBPCF
Helix BioPharma Corp., headquartered in Toronto, Canada, is an immune-oncology company dedicated to developing innovative cancer therapies. The company's primary focus is on its DOS47 platform, which includes L-DOS47 for the treatment of non-small cell lung cancer (NSCLC) and V-DOS47, targeting the vascular epithelial growth factor receptor 2 (VEGFR2). These therapies are designed to leverage the body's immune system to fight cancer cells. Helix BioPharma collaborates with leading cancer research institutions such as Moffitt Cancer Center and University Hospital Tuebingen to advance the development and understanding of its drug candidates. These collaborations aim to investigate the pharmacodynamics of L-DOS47, determine the benefits of combining it with immune checkpoint inhibitors, and assess its therapeutic response in cancer models expressing CEACAM6, utilizing advanced preclinical metabolic imaging. The company's strategic approach involves targeting specific cancer pathways and utilizing innovative drug delivery methods to improve treatment outcomes. With a small team of 7 employees, Helix BioPharma operates in a highly competitive biotechnology sector, striving to make a significant impact in the field of cancer treatment.
What They Do
- Develops L-DOS47 for the treatment of non-small cell lung cancer.
- Develops V-DOS47 that targets the vascular epithelial growth factor receptor 2.
- Conducts research and development in the field of immune-oncology.
- Collaborates with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47.
- Collaborates with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models.
- Focuses on targeted therapies to leverage the body's immune system to fight cancer cells.
Business Model
- Develops and patents novel cancer therapies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through research grants and collaboration agreements.
- Seeks regulatory approval for its drug candidates.
Industry Context
Helix BioPharma operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The immune-oncology segment, in particular, is experiencing rapid growth due to the increasing understanding of the role of the immune system in fighting cancer. Key trends include the development of personalized medicine, targeted therapies, and combination therapies. Helix BioPharma's focus on the DOS47 platform positions it within this innovative space, but it faces competition from larger, more established pharmaceutical companies with greater resources.
Key Customers
- Cancer patients suffering from non-small cell lung cancer.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Research institutions and universities.
Financials
Chart & Info
Helix BioPharma Corp. (HBPCF) stock price: Price data unavailable
Latest News
-
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
thenewswire.com · Feb 24, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HBPCF.
Price Targets
Wall Street price target analysis for HBPCF.
MoonshotScore
What does this score mean?
The MoonshotScore rates HBPCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas Mehrling
CEO
Thomas Mehrling serves as the CEO of Helix BioPharma Corp. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy and business development. He has held various leadership positions in companies involved in drug development and commercialization. His expertise lies in guiding companies through the complex process of bringing novel therapies to market, from preclinical research to regulatory approval and commercial launch.
Track Record: Under Thomas Mehrling's leadership, Helix BioPharma Corp. has focused on advancing its DOS47 platform and securing collaborations with leading cancer research institutions. Key milestones include the ongoing clinical trials for L-DOS47 and the partnerships with Moffitt Cancer Center and University Hospital Tuebingen. He is responsible for steering the company's strategic direction and overseeing its research and development efforts.
HBPCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Helix BioPharma Corp. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase investment risk. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited disclosure requirements on the OTC market.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable financial information.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Collaboration agreements with reputable cancer research institutions.
- Focus on innovative cancer therapies.
- Patent protection for key drug candidates.
- Presence of a management team with experience in the pharmaceutical industry.
- Ongoing clinical trials for L-DOS47.
What Investors Ask About Helix BioPharma Corp. (HBPCF)
What does Helix BioPharma Corp. do?
Helix BioPharma Corp. is a Canadian immune-oncology company focused on developing innovative cancer therapies. Its primary focus is on the DOS47 platform, which includes L-DOS47 for the treatment of non-small cell lung cancer (NSCLC) and V-DOS47, targeting the vascular epithelial growth factor receptor 2 (VEGFR2). The company collaborates with leading cancer research institutions to advance the development and understanding of its drug candidates, aiming to improve treatment outcomes through targeted and immune-based approaches.
What do analysts say about HBPCF stock?
As of March 16, 2026, there is no readily available analyst consensus on HBPCF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-30.96), reflect the company's current lack of profitability and ongoing investment in research and development. Growth considerations revolve around the successful advancement of its drug candidates through clinical trials and potential partnerships. Investors should conduct their own thorough research and consider the risks associated with investing in a small-cap, OTC-listed biotechnology company.
What are the main risks for HBPCF?
The main risks for Helix BioPharma Corp. include clinical trial failures, competition from larger pharmaceutical companies, regulatory hurdles, and limited financial resources. As a small-cap, OTC-listed company, HBPCF faces challenges in securing funding and navigating the complex regulatory landscape. The success of its drug candidates, particularly L-DOS47 and V-DOS47, is critical to its long-term viability. Investors should be aware of the high-risk nature of investing in early-stage biotechnology companies and the potential for significant losses.
What are the key factors to evaluate for HBPCF?
Helix BioPharma Corp. (HBPCF) currently holds an AI score of 45/100, indicating low score. Key strength: Innovative DOS47 platform targeting cancer cells.. Primary risk to monitor: Potential: Clinical trial failures for L-DOS47 or V-DOS47.. This is not financial advice.
How frequently does HBPCF data refresh on this page?
HBPCF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HBPCF's recent stock price performance?
Recent price movement in Helix BioPharma Corp. (HBPCF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative DOS47 platform targeting cancer cells.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HBPCF overvalued or undervalued right now?
Determining whether Helix BioPharma Corp. (HBPCF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HBPCF?
Before investing in Helix BioPharma Corp. (HBPCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 16, 2026.
- OTC market data may be limited or inconsistent.
- Analyst consensus may not be available for all OTC-listed companies.